ArticleScience advances2021
NSG-Pro mouse model for uncovering resistance mechanisms and unique vulnerabilities in human luminal breast cancers.
Abstract read
In one paragraph
Article in Science advances, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- The latest progress of personalized drug screening and therapy research for common clinical tumors through the PDX model platform.Journal of pharmaceutical analysis · 2025Review
- Prolactin and DNA damage trigger an anti-breast cancer cell immune response.Frontiers in endocrinology · 2025Article
- Leveraging preclinical models of metastatic breast cancer.Biochimica et biophysica acta. Reviews on cancer · 2024Review
- The Power and Promise of Patient-Derived Xenografts of Human Breast Cancer.Cold Spring Harbor perspectives in medicine · 2024Review
- Stat5 induces androgen receptor (Science advances · 2024Article
- Frequent upregulation of HER2 protein in hormone-receptor-positive HER2-negative breast cancer after short-term neoadjuvant endocrine therapy.Breast cancer research and treatment · 2023Article
- Frequent Upregulation Of HER2 Protein In Hormone Receptor-Positive HER2-Negative Breast Cancer After Short-Term Neoadjuvant Endocrine Therapy.Research square · 2023Article
- Functional biomaterials for biomimetic 3D in vitro tumor microenvironment modeling.In vitro models · 2023Review
- Breast Cancer and Prolactin - New Mechanisms and Models.Endocrinology · 2022Review
- Prolactin: The Third Hormone in Breast Cancer.Frontiers in endocrinology · 2022Review
- Terminal differentiation and anti-tumorigenic effects of prolactin in breast cancer.Frontiers in endocrinology · 2022Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
25 authors.
Yunguang SunDepartment of Pathology, Medical College of Wisconsin, Milwaukee, WI 53226, USA.ORCID 0000-0003-4004-9514
Ning YangDepartment of Pathology, Medical College of Wisconsin, Milwaukee, WI 53226, USA.
Fransiscus E UtamaDepartment of Pathology, Medical College of Wisconsin, Milwaukee, WI 53226, USA.
Sameer S UdhaneDepartment of Pathology, Medical College of Wisconsin, Milwaukee, WI 53226, USA.ORCID 0000-0002-9651-8159
Junling ZhangDepartment of Pathology, Medical College of Wisconsin, Milwaukee, WI 53226, USA.
Amy R PeckDepartment of Pathology, Medical College of Wisconsin, Milwaukee, WI 53226, USA.
Alicia YanacDepartment of Pathology, Medical College of Wisconsin, Milwaukee, WI 53226, USA.
Katherine DuffeyDepartment of Pathology, Medical College of Wisconsin, Milwaukee, WI 53226, USA.
John F LangenheimDepartment of Pathology, Medical College of Wisconsin, Milwaukee, WI 53226, USA.ORCID 0000-0001-8222-5286
Vindhya UdhaneDepartment of Pathology, Medical College of Wisconsin, Milwaukee, WI 53226, USA.
Guanjun XiaDepartment of Pathology, Medical College of Wisconsin, Milwaukee, WI 53226, USA.ORCID 0000-0001-6660-7268
Jess F PetersonDepartment of Pathology, Medical College of Wisconsin, Milwaukee, WI 53226, USA.
Julie M JornsDepartment of Pathology, Medical College of Wisconsin, Milwaukee, WI 53226, USA.ORCID 0000-0002-7777-6670
Marja T NevalainenDepartment of Pathology, Medical College of Wisconsin, Milwaukee, WI 53226, USA.ORCID 0000-0003-2273-6396
Romain RouetImmunology Division, University of New South Wales, Darlinghurst, NSW 2010, Australia.ORCID 0000-0003-4210-9613
Peter SchofieldImmunology Division, University of New South Wales, Darlinghurst, NSW 2010, Australia.ORCID 0000-0002-8046-3667
Daniel ChristImmunology Division, University of New South Wales, Darlinghurst, NSW 2010, Australia.ORCID 0000-0002-7313-3977
Christopher J OrmandyGarvan Institute of Medical Research and St. Vincent's Clinical School, University of New South Wales, Darlinghurst, NSW 2010, Australia.ORCID 0000-0002-2504-7919
Anne L RosenbergDepartment of Surgery, Thomas Jefferson University, Philadelphia, PA 19107, USA.
Inna ChervonevaDepartment of Pharmacology, Division of Biostatistics, Thomas Jefferson University, Philadelphia, PA 19107, USA.ORCID 0000-0002-9104-4505
Shirng-Wern TsaihDepartment of Physiology, Medical College of Wisconsin, Milwaukee, WI 53226, USA.ORCID 0000-0002-9836-4659
Michael J FlisterDepartment of Physiology, Medical College of Wisconsin, Milwaukee, WI 53226, USA.ORCID 0000-0001-8030-7739
Serge Y FuchsDepartment of Biomedical Sciences, University of Pennsylvania School of Veterinary Medicine, Philadelphia, PA 19104, USA.ORCID 0000-0002-0136-5103
Kay-Uwe WagnerKarmanos Cancer Institute, Wayne State University, Detroit, MI 48201, USA.ORCID 0000-0002-5081-0226
Hallgeir RuiDepartment of Pathology, Medical College of Wisconsin, Milwaukee, WI 53226, USA.ORCID 0000-0002-8778-261X
Funding
Leveraging genetic mapping for personalized targeting of breast cancer microenvironmentR01CA193343 · NCI · MEDICAL COLLEGE OF WISCONSIN · PI Amit Joshi · 2015 to 2026
$3.5MStatistical Methods For Quantitative Immunohistochemistry BiomarkersR01CA222847 · NCI · THOMAS JEFFERSON UNIVERSITY · PI CHERVONEVA, INNA · 2019 to 2023
$1.8MProlactin pathways and metastatic progression of ER-positive breast cancerR01CA188575 · NCI · THOMAS JEFFERSON UNIVERSITY · PI RUI, HALLGEIR · 2015 to 2019
$1.8MExperimental Modeling of Human Breast Cancer in MiceR01CA118740 · NCI · THOMAS JEFFERSON UNIVERSITY · PI RUI, HALLGEIR · 2008 to 2012
$1.8MJAK1 Signaling in Pancreatic Cancer Initiation and ProgressionR01CA202917 · NCI · WAYNE STATE UNIVERSITY · PI WAGNER, KAY-UWE · 2017 to 2021
$1.6MMolecular features of patient-derived luminal breast cancer xenotransplant modelsR21CA185918 · NCI · THOMAS JEFFERSON UNIVERSITY · PI RUI, HALLGEIR · 2014 to 2015
$371kNCI NIH HHS R01 CA118740NCI NIH HHS R01 CA188575NCI NIH HHS R01 CA193343NCI NIH HHS R01 CA202917NCI NIH HHS R01 CA222847NCI NIH HHS R21 CA185918
Abstract
Most breast cancer deaths are caused by estrogen receptor-α–positive (ER
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.